Literature DB >> 17130898

Immunopathogenesis of hepatitis B virus infection.

J Judy Chang1, Sharon R Lewin.   

Abstract

Hepatitis B virus (HBV) infection is a non-cytopathic hepatotropic virus that can lead to severe liver disease including acute hepatitis, cirrhosis and hepatocellular carcinoma. Successful clearance of the virus as well as the establishment of liver disease is largely driven by a complex interaction between the virus and the host immune response. In this review, the immunological events, including both the innate and adaptive immune response are discussed in the setting of both acute and chronic HBV infection and liver disease.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17130898     DOI： 10.1038/sj.icb.7100009

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN： 0818-9641            Impact factor:   5.126


  60 in total

Review 1.  Gut microbiota modulate the immune effect against hepatitis B virus infection.

Authors:  D Xu; Y Huang; J Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-14       Impact factor: 3.267

Review 2.  Management of patients with hepatitis B who require immunosuppressive therapy.

Authors:  Jessica P Hwang; Anna S-F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 46.802

3.  Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO.

Authors:  Yuan Wang; Lei Cui; Guifang Yang; Jianbo Zhan; Liang Guo; Yu Chen; Chengpeng Fan; Dan Liu; Deyin Guo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 4.  Immune restoration diseases reflect diverse immunopathological mechanisms.

Authors:  Patricia Price; David M Murdoch; Upasna Agarwal; Sharon R Lewin; Julian H Elliott; Martyn A French
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

5.  Activated natural killer cells accelerate liver damage in patients with chronic hepatitis B virus infection.

Authors:  Q Zheng; Y Y Zhu; J Chen; Y B Ye; J Y Li; Y R Liu; M L Hu; Y C Zheng; J J Jiang
Journal:  Clin Exp Immunol       Date:  2015-04-12       Impact factor: 4.330

6.  The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center.

Authors:  S K Bae; T Gushima; N Saito; I Yamanaka; T Shimokawa; Y Matsuo; S Yoshida; I Kawano; H Henzan; S Shimoda; T Eto; K Takahashi
Journal:  Bone Marrow Transplant       Date:  2016-06-06       Impact factor: 5.483

7.  Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.

Authors:  N Obeng-Adjei; D K Choo; J Saini; J Yan; P Pankhong; A Parikh; J S Chu; D B Weiner
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

8.  Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals.

Authors:  Christina M Martin; Jeffrey A Welge; Norah J Shire; Mohamed T Shata; Kenneth E Sherman; Jason T Blackard
Journal:  Cytokine       Date:  2009-07-21       Impact factor: 3.861

9.  Single-nucleotide polymorphism at CYP27B1-1260, but not VDR Taq I, is possibly associated with persistent hepatitis B virus infection.

Authors:  Qianqian Zhu; Na Li; Qunying Han; Zhu Li; Guoyu Zhang; Fang Li; Pingping Zhang; Jinghong Chen; Yi Lv; Zhengwen Liu
Journal:  Genet Test Mol Biomarkers       Date:  2012-09

Review 10.  Crosstalk between innate and adaptive immunity in hepatitis B virus infection.

Authors:  Li Wang; Kai Wang; Zhi-Qiang Zou
Journal:  World J Hepatol       Date:  2015-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.